G01N 2500/02
Screening involving studying the effect of compounds c on the interaction between
Official title: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
G01N2500/02 (Screening involving studying the effect of compounds c on the interaction between) appears on 1,294 US grants and 2,473 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,294
- Published applications
- 2,473
- Assignees
- 1,068
- Inventors
- 4,827
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 12 | 0 |
| 1999 | 17 | 0 |
| 2000 | 12 | 0 |
| 2001 | 17 | 6 |
| 2002 | 26 | 76 |
| 2003 | 23 | 159 |
| 2004 | 27 | 120 |
| 2005 | 33 | 158 |
| 2006 | 58 | 137 |
| 2007 | 61 | 126 |
| 2008 | 59 | 123 |
| 2009 | 53 | 155 |
| 2010 | 74 | 168 |
| 2011 | 91 | 119 |
| 2012 | 76 | 123 |
| 2013 | 67 | 83 |
| 2014 | 69 | 106 |
| 2015 | 73 | 148 |
| 2016 | 57 | 101 |
| 2017 | 57 | 86 |
| 2018 | 53 | 66 |
| 2019 | 54 | 80 |
| 2020 | 43 | 60 |
| 2021 | 36 | 61 |
| 2022 | 32 | 56 |
| 2023 | 37 | 55 |
| 2024 | 21 | 33 |
| 2025 | 35 | 42 |
| 2026 | 15 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for transducing protein-protein interactions6 Oct 2026US 12,753,403 B2ETH Zurich
- Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation25 Aug 2026US 12,715,899 B2Seoul National University Hospital
- Method for producing peptide containing non-natural amino acid26 May 2026US 12,637,494 B2Chugai Seiyaku Kabushiki Kaisha
- CD71 binding fibronectin type III domains31 Mar 2026US 12,589,159 B2ARO Biotherapeutics Company
- Quantum dot conjugated virus spike protein for cell-based bio-sensing systems and drug screening31 Mar 2026US 12,590,961 B2The Government of the United States of America, as represented by the Secretary of the Navy
- Methods and tools for detecting the impact of compounds on protein, rna or dna interactions8 Oct 2026US 2026/0309718 A1Iktos
- Method for the in vitro diagnosis of a neurodegenerative disease1 Oct 2026US 2026/0298947 A1Institut National de la Sante et de la Recherche Medicale
- Screening method for compound inducing autophagy17 Sep 2026US 2026/0276625 A1Tohoku University
- Compositions and methods for the identification of inhibitors of and treatment for ectopic calcification3 Sep 2026US 2026/0256761 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Method for evaluating receptor-type tyrosine kinase activity20 Aug 2026US 2026/0243779 A1Riken
Most cited
By later US patents
- Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto180US 5,480,968 AThe United States of America as represented by the Department of Health and Human Services · 1996
- DNA segment encoding a gene for a receptor related to the epidermal growth factor receptor146US 5,183,884 AUnited States of America · 1993
- Transgenic animals harboring APP allele having swedish mutation142US 5,612,486 AAthena Neurosciences, Inc. · 1997
- Modulators of ATP-binding cassette transporters121US 7,776,905 B2Vertex Pharmaceuticals Incorporated · 2010
- Compositions for manipulating the lifespan and stress response of cells and organisms105US 7,544,497 B2BIOMOL International L.P. · 2009